RecruitingEarly Phase 1NCT04390009

Entire-body PET Scans for Multiple Sclerosis

Exploratory Study of Entire-body PET Scans for Multiple Sclerosis


Sponsor

Brain Health Alliance

Enrollment

20 participants

Start Date

Sep 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.


Eligibility

Min Age: 25 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study uses a new type of PET scan that can image the entire body at once to study inflammation in people with multiple sclerosis (MS). The goal is to see if this advanced imaging can better detect disease activity throughout the body, including the brain and spinal cord, compared to standard imaging. **You may be eligible if...** - You have a confirmed diagnosis of multiple sclerosis (MS), diagnosed by a neurologist - OR you are a healthy volunteer willing to participate for comparison - You are able to lie still on a scanner bed for 10 to 20 minutes **You may NOT be eligible if...** - You have other significant neurological or psychiatric illnesses unrelated to MS - You are pregnant or breastfeeding - You have diabetes or other metabolic/endocrine disorders - You have an active infection - You have a history of metastatic or invasive cancer - You have had recent surgery, chemotherapy, or radiation therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEntire-body PET-CT scans

Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.

DRUGAmyvid radiopharmaceutical

Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants


Locations(1)

Brain Health Alliance

Ladera Ranch, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04390009


Related Trials